JP2009534306A - 軽度から中等度の尋常性ざ瘡の局所治療のためのバルプロ酸の使用 - Google Patents
軽度から中等度の尋常性ざ瘡の局所治療のためのバルプロ酸の使用 Download PDFInfo
- Publication number
- JP2009534306A JP2009534306A JP2009501893A JP2009501893A JP2009534306A JP 2009534306 A JP2009534306 A JP 2009534306A JP 2009501893 A JP2009501893 A JP 2009501893A JP 2009501893 A JP2009501893 A JP 2009501893A JP 2009534306 A JP2009534306 A JP 2009534306A
- Authority
- JP
- Japan
- Prior art keywords
- vpa
- treatment
- histone deacetylase
- acne
- use according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- NIJJYAXOARWZEE-UHFFFAOYSA-N Valproic acid Chemical compound CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 title claims abstract 14
- 229960000604 valproic acid Drugs 0.000 title claims abstract 10
- 208000002874 Acne Vulgaris Diseases 0.000 title claims abstract 7
- 206010000496 acne Diseases 0.000 title claims abstract 7
- 230000000699 topical effect Effects 0.000 title claims abstract 5
- 239000003814 drug Substances 0.000 claims abstract 5
- SHGAZHPCJJPHSC-NUEINMDLSA-N Isotretinoin Chemical compound OC(=O)C=C(C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NUEINMDLSA-N 0.000 claims abstract 2
- 229960005280 isotretinoin Drugs 0.000 claims abstract 2
- 229940121372 histone deacetylase inhibitor Drugs 0.000 claims 14
- 239000003276 histone deacetylase inhibitor Substances 0.000 claims 14
- 239000013543 active substance Substances 0.000 claims 10
- 229940124597 therapeutic agent Drugs 0.000 claims 4
- 239000003242 anti bacterial agent Substances 0.000 claims 3
- 239000000417 fungicide Substances 0.000 claims 3
- 229940125697 hormonal agent Drugs 0.000 claims 3
- 230000003902 lesion Effects 0.000 claims 3
- 102000003964 Histone deacetylase Human genes 0.000 claims 2
- 108090000353 Histone deacetylase Proteins 0.000 claims 2
- -1 TPX-HA analog (CHAP) Chemical compound 0.000 claims 2
- 230000003115 biocidal effect Effects 0.000 claims 2
- GYKLFBYWXZYSOW-UHFFFAOYSA-N butanoyloxymethyl 2,2-dimethylpropanoate Chemical compound CCCC(=O)OCOC(=O)C(C)(C)C GYKLFBYWXZYSOW-UHFFFAOYSA-N 0.000 claims 2
- 230000001186 cumulative effect Effects 0.000 claims 2
- 230000000855 fungicidal effect Effects 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 150000004492 retinoid derivatives Chemical class 0.000 claims 2
- OHRURASPPZQGQM-GCCNXGTGSA-N romidepsin Chemical compound O1C(=O)[C@H](C(C)C)NC(=O)C(=C/C)/NC(=O)[C@H]2CSSCC\C=C\[C@@H]1CC(=O)N[C@H](C(C)C)C(=O)N2 OHRURASPPZQGQM-GCCNXGTGSA-N 0.000 claims 2
- 210000002966 serum Anatomy 0.000 claims 2
- 108010060597 trapoxin A Proteins 0.000 claims 2
- QRPSQQUYPMFERG-LFYBBSHMSA-N (e)-5-[3-(benzenesulfonamido)phenyl]-n-hydroxypent-2-en-4-ynamide Chemical compound ONC(=O)\C=C\C#CC1=CC=CC(NS(=O)(=O)C=2C=CC=CC=2)=C1 QRPSQQUYPMFERG-LFYBBSHMSA-N 0.000 claims 1
- BWDQBBCUWLSASG-MDZDMXLPSA-N (e)-n-hydroxy-3-[4-[[2-hydroxyethyl-[2-(1h-indol-3-yl)ethyl]amino]methyl]phenyl]prop-2-enamide Chemical compound C=1NC2=CC=CC=C2C=1CCN(CCO)CC1=CC=C(\C=C\C(=O)NO)C=C1 BWDQBBCUWLSASG-MDZDMXLPSA-N 0.000 claims 1
- NEAQRZUHTPSBBM-UHFFFAOYSA-N 2-hydroxy-3,3-dimethyl-7-nitro-4h-isoquinolin-1-one Chemical compound C1=C([N+]([O-])=O)C=C2C(=O)N(O)C(C)(C)CC2=C1 NEAQRZUHTPSBBM-UHFFFAOYSA-N 0.000 claims 1
- JTDYUFSDZATMKU-UHFFFAOYSA-N 6-(1,3-dioxo-2-benzo[de]isoquinolinyl)-N-hydroxyhexanamide Chemical compound C1=CC(C(N(CCCCCC(=O)NO)C2=O)=O)=C3C2=CC=CC3=C1 JTDYUFSDZATMKU-UHFFFAOYSA-N 0.000 claims 1
- DBBYYRWVNDQECM-CDWOPPGASA-N CG-1521 Chemical compound ONC(=O)\C=C\C=C\C=C\C1=CC=CC=C1 DBBYYRWVNDQECM-CDWOPPGASA-N 0.000 claims 1
- 108010002156 Depsipeptides Proteins 0.000 claims 1
- DLVJMFOLJOOWFS-UHFFFAOYSA-N Depudecin Natural products CC(O)C1OC1C=CC1C(C(O)C=C)O1 DLVJMFOLJOOWFS-UHFFFAOYSA-N 0.000 claims 1
- 206010015150 Erythema Diseases 0.000 claims 1
- PTJGLFIIZFVFJV-UHFFFAOYSA-N N'-hydroxy-N-(3-pyridinyl)octanediamide Chemical compound ONC(=O)CCCCCCC(=O)NC1=CC=CN=C1 PTJGLFIIZFVFJV-UHFFFAOYSA-N 0.000 claims 1
- HRNLUBSXIHFDHP-UHFFFAOYSA-N N-(2-aminophenyl)-4-[[[4-(3-pyridinyl)-2-pyrimidinyl]amino]methyl]benzamide Chemical compound NC1=CC=CC=C1NC(=O)C(C=C1)=CC=C1CNC1=NC=CC(C=2C=NC=CC=2)=N1 HRNLUBSXIHFDHP-UHFFFAOYSA-N 0.000 claims 1
- 108050002485 Sirtuin Proteins 0.000 claims 1
- 102000011990 Sirtuin Human genes 0.000 claims 1
- 229930189037 Trapoxin Natural products 0.000 claims 1
- GXVXXETYXSPSOA-UHFFFAOYSA-N Trapoxin A Natural products C1OC1C(=O)CCCCCC(C(NC(CC=1C=CC=CC=1)C(=O)N1)=O)NC(=O)C2CCCCN2C(=O)C1CC1=CC=CC=C1 GXVXXETYXSPSOA-UHFFFAOYSA-N 0.000 claims 1
- RTKIYFITIVXBLE-UHFFFAOYSA-N Trichostatin A Natural products ONC(=O)C=CC(C)=CC(C)C(=O)C1=CC=C(N(C)C)C=C1 RTKIYFITIVXBLE-UHFFFAOYSA-N 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 229940088710 antibiotic agent Drugs 0.000 claims 1
- NCNRHFGMJRPRSK-MDZDMXLPSA-N belinostat Chemical compound ONC(=O)\C=C\C1=CC=CC(S(=O)(=O)NC=2C=CC=CC=2)=C1 NCNRHFGMJRPRSK-MDZDMXLPSA-N 0.000 claims 1
- 229940054066 benzamide antipsychotics Drugs 0.000 claims 1
- 150000003936 benzamides Chemical class 0.000 claims 1
- 125000002619 bicyclic group Chemical group 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 125000004122 cyclic group Chemical group 0.000 claims 1
- DLVJMFOLJOOWFS-INMLLLKOSA-N depudecin Chemical compound C[C@@H](O)[C@@H]1O[C@H]1\C=C\[C@H]1[C@H]([C@H](O)C=C)O1 DLVJMFOLJOOWFS-INMLLLKOSA-N 0.000 claims 1
- 235000014113 dietary fatty acids Nutrition 0.000 claims 1
- 231100000321 erythema Toxicity 0.000 claims 1
- 230000001747 exhibiting effect Effects 0.000 claims 1
- 229930195729 fatty acid Natural products 0.000 claims 1
- 239000000194 fatty acid Substances 0.000 claims 1
- 150000004665 fatty acids Chemical class 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000002207 metabolite Substances 0.000 claims 1
- 230000000813 microbial effect Effects 0.000 claims 1
- OYKBQNOPCSXWBL-SNAWJCMRSA-N n-hydroxy-3-[(e)-3-(hydroxyamino)-3-oxoprop-1-enyl]benzamide Chemical compound ONC(=O)\C=C\C1=CC=CC(C(=O)NO)=C1 OYKBQNOPCSXWBL-SNAWJCMRSA-N 0.000 claims 1
- FWZRWHZDXBDTFK-ZHACJKMWSA-N panobinostat Chemical compound CC1=NC2=CC=C[CH]C2=C1CCNCC1=CC=C(\C=C\C(=O)NO)C=C1 FWZRWHZDXBDTFK-ZHACJKMWSA-N 0.000 claims 1
- 229960005184 panobinostat Drugs 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 239000000651 prodrug Substances 0.000 claims 1
- 229940002612 prodrug Drugs 0.000 claims 1
- VAZAPHZUAVEOMC-UHFFFAOYSA-N tacedinaline Chemical compound C1=CC(NC(=O)C)=CC=C1C(=O)NC1=CC=CC=C1N VAZAPHZUAVEOMC-UHFFFAOYSA-N 0.000 claims 1
- 239000012049 topical pharmaceutical composition Substances 0.000 claims 1
- GXVXXETYXSPSOA-UFEOFEBPSA-N trapoxin A Chemical compound C([C@H]1C(=O)N2CCCC[C@@H]2C(=O)N[C@H](C(N[C@@H](CC=2C=CC=CC=2)C(=O)N1)=O)CCCCCC(=O)[C@H]1OC1)C1=CC=CC=C1 GXVXXETYXSPSOA-UFEOFEBPSA-N 0.000 claims 1
- RTKIYFITIVXBLE-QEQCGCAPSA-N trichostatin A Chemical compound ONC(=O)/C=C/C(/C)=C/[C@@H](C)C(=O)C1=CC=C(N(C)C)C=C1 RTKIYFITIVXBLE-QEQCGCAPSA-N 0.000 claims 1
- WAEXFXRVDQXREF-UHFFFAOYSA-N vorinostat Chemical compound ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1 WAEXFXRVDQXREF-UHFFFAOYSA-N 0.000 claims 1
- 229960000237 vorinostat Drugs 0.000 claims 1
- MSRILKIQRXUYCT-UHFFFAOYSA-M valproate semisodium Chemical compound [Na+].CCCC(C(O)=O)CCC.CCCC(C([O-])=O)CCC MSRILKIQRXUYCT-UHFFFAOYSA-M 0.000 abstract 6
- 229940079593 drug Drugs 0.000 abstract 1
- 238000002651 drug therapy Methods 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Cosmetics (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06006847A EP1839656A1 (en) | 2006-03-31 | 2006-03-31 | Use of valproic acid for the topical treatment of mild to moderate acne vulgaris |
| PCT/EP2007/002201 WO2007112832A1 (en) | 2006-03-31 | 2007-03-13 | Use of valproic acid for the topical treatment of mild to moderate acne vulgaris |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009534306A true JP2009534306A (ja) | 2009-09-24 |
| JP2009534306A5 JP2009534306A5 (OSRAM) | 2010-03-18 |
Family
ID=36498743
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009501893A Withdrawn JP2009534306A (ja) | 2006-03-31 | 2007-03-13 | 軽度から中等度の尋常性ざ瘡の局所治療のためのバルプロ酸の使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20090186809A1 (OSRAM) |
| EP (2) | EP1839656A1 (OSRAM) |
| JP (1) | JP2009534306A (OSRAM) |
| AT (1) | ATE476972T1 (OSRAM) |
| DE (1) | DE602007008385D1 (OSRAM) |
| WO (1) | WO2007112832A1 (OSRAM) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8492438B2 (en) * | 2002-04-26 | 2013-07-23 | Asan Laboratories Company (Cayman), Limited | Treatment skin disorders |
| EP1491188A1 (en) * | 2003-06-25 | 2004-12-29 | G2M Cancer Drugs AG | Topical use of valproic acid for the prevention or treatment of skin disorders |
| EP2946810A1 (en) | 2005-02-03 | 2015-11-25 | TopoTarget UK Limited | Combination therapy using an HDAC inhibitor and Vincristine for treating cancer |
| CN102579417B (zh) | 2005-05-13 | 2014-11-26 | 托波塔吉特英国有限公司 | Hdac抑制剂的药物制剂 |
| EP2361619A1 (en) | 2005-11-10 | 2011-08-31 | TopoTarget UK Limited | Histone deacetylase (hdac) inhibitors (pxd-101) alone for the treatment of hematological cancer |
| CA2700173C (en) * | 2007-09-25 | 2016-10-11 | Topotarget Uk Limited | Methods of synthesis of certain hydroxamic acid compounds |
| WO2009109861A1 (en) * | 2008-03-07 | 2009-09-11 | Topotarget A/S | Methods of treatment employing prolonged continuous infusion of belinostat |
| CA2746506A1 (en) | 2008-12-08 | 2010-07-08 | Northwestern University | Method of modulating hsf-1 |
| GB0900555D0 (en) * | 2009-01-14 | 2009-02-11 | Topotarget As | New methods |
| WO2011097549A2 (en) * | 2010-02-05 | 2011-08-11 | Asan Laboratories Company (Cayman), Limited | Treatment skin disorders |
| KR101733189B1 (ko) | 2010-10-06 | 2017-05-08 | (주)아모레퍼시픽 | 손톱 또는 발톱 성장 촉진용 조성물 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1491188A1 (en) * | 2003-06-25 | 2004-12-29 | G2M Cancer Drugs AG | Topical use of valproic acid for the prevention or treatment of skin disorders |
| DE602004014723D1 (de) * | 2004-04-30 | 2008-08-14 | Desitin Arzneimittel Gmbh | Histondeacetylase-Inhibitor enthaltende Formulierung zur zweiphasigen Freisetzung |
| PL1776358T3 (pl) * | 2004-07-28 | 2009-10-30 | Janssen Pharmaceutica Nv | Pochodne podstawionej propenylopiperazyny jako nowe inhibitory deacetylazy histonowej |
-
2006
- 2006-03-31 EP EP06006847A patent/EP1839656A1/en not_active Withdrawn
-
2007
- 2007-03-13 JP JP2009501893A patent/JP2009534306A/ja not_active Withdrawn
- 2007-03-13 AT AT07711939T patent/ATE476972T1/de not_active IP Right Cessation
- 2007-03-13 DE DE602007008385T patent/DE602007008385D1/de active Active
- 2007-03-13 EP EP07711939A patent/EP2001458B1/en not_active Not-in-force
- 2007-03-13 US US12/295,359 patent/US20090186809A1/en not_active Abandoned
- 2007-03-13 WO PCT/EP2007/002201 patent/WO2007112832A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| EP2001458B1 (en) | 2010-08-11 |
| EP2001458A1 (en) | 2008-12-17 |
| DE602007008385D1 (de) | 2010-09-23 |
| WO2007112832A1 (en) | 2007-10-11 |
| US20090186809A1 (en) | 2009-07-23 |
| EP1839656A1 (en) | 2007-10-03 |
| ATE476972T1 (de) | 2010-08-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2001458B1 (en) | Use of valproic acid for the topical treatment of mild to moderate acne vulgaris | |
| EP1635808B1 (en) | Topical use of valproic acid for the prevention or treatment of psoriasis and acne | |
| JP3522220B2 (ja) | 細胞媒介性免疫病の処置 | |
| KR20170013854A (ko) | 저항성 여드름을 위한 치료 | |
| EP2127636A1 (en) | Anti-wrinkle agent and adam inhibitor | |
| JP7587916B2 (ja) | 外用乳化組成物 | |
| JP5891651B2 (ja) | 角層細胞分化正常化用皮膚外用剤 | |
| EP2265268A2 (en) | Stable fixed dose topical formulation | |
| JP6967369B2 (ja) | 乳化組成物 | |
| JP6851139B2 (ja) | 外用組成物 | |
| JP7312527B2 (ja) | 乳化組成物 | |
| JP6735587B2 (ja) | 外用組成物 | |
| JP2016000721A (ja) | 外用剤組成物及び抗炎症作用増強剤 | |
| JP2020033311A (ja) | 皮膚外用組成物 | |
| JP7446711B2 (ja) | 皮膚外用組成物 | |
| JP2005179318A (ja) | 抗炎症皮膚外用医薬部外品 | |
| JP5022568B2 (ja) | エッセンス剤形の皮膚外用剤 | |
| JP7329910B2 (ja) | 皮膚外用組成物 | |
| JP2019218345A (ja) | 外用組成物 | |
| JP7299682B2 (ja) | 皮膚外用組成物 | |
| JP2018002651A (ja) | 慢性角化型湿疹改善剤 | |
| JP2025021235A (ja) | 乳化外用組成物 | |
| JP4771453B2 (ja) | エッセンス剤形の皮膚外用剤 | |
| EP2381916A2 (en) | Hydrogel composition for the treatment of dermatological disorders | |
| WO2020137683A1 (ja) | 外用組成物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100201 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20100201 |
|
| A761 | Written withdrawal of application |
Free format text: JAPANESE INTERMEDIATE CODE: A761 Effective date: 20100929 |